The Lessons of Asilomar for Today’s Science
By Alexander Capron,
The New York Times
| 05. 28. 2015
Untitled Document
There is a precedent for establishing internationally agreed-upon limits for new science, though it can be hard to do.
In 1973, scientists who were using novel molecular techniques to splice DNA between different organisms asked the National Academy of Sciences to consider the potential hazards as they might affect the public. In July 1974, an Academy-appointed committee publicly called for a large category of experiments to be suspended until leaders in the field could plan a way forward. Such a self-imposed moratorium on basic research was unprecedented, but it worked.
A hundred and fifty scientists and physicians from around the world gathered in February 1975 at the Asilomar conference center near Monterey, California, in what one scientist termed an amazing show of “self denial and social responsibility in the face of strong intellectual temptation” to continue the experiments.
The outcome of the meeting was equally impressive. Categories of experiments were graded by their riskiness: Some were deemed excessively dangerous and kept off-limits, while others were to be allowed once the appropriate biological and physical means of risk-containment had...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...